SCHEMBL7527434

SCHEMBL7527434

COCCOC(=O)N1CCc2[nH]cnc2C1c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 3/20 0.63
GAA P10253 1/20 0.42
RAB9A P51151 2/20 0.39
LMNA P02545 3/20 0.38
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
PTGDR2 Q9Y5Y4 3/20 0.38
TRPV1 Q8NER1 1/20 0.36
ALDH1A1 P00352 2/20 0.35
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
XBP1 P17861 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MMP2 P08253 3/20 0.35
MMP3 P08254 3/20 0.35
MMP9 P14780 3/20 0.35
MMP8 P22894 3/20 0.35
MMP13 P45452 3/20 0.35
MMP1 P03956 1/20 0.35
CHRM5 P08912 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7525097 0.81 AOC3 (0.48) AOC3RAB9ALMNAHTTNPSR1
SCHEMBL7527430 0.81 AOC3 (0.52) AOC3RAB9ALMNAHTTNPSR1
SCHEMBL7534337 0.81 AOC3 (0.56) AOC3LMNAHTTPTGDR2ALDH1A1
Trifluoroacetic Acid SCHEMBL7529917 0.80 AOC3 (0.52) AOC3PTGDR2
SCHEMBL7528897 0.79 AOC3 (0.54) AOC3LMNAHTTPTGDR2ALDH1A1
SCHEMBL11515027 0.78 AOC3 (0.47) AOC3RAB9ATRPV1
SCHEMBL7570588 0.78 AOC3 (0.46) AOC3GAARAB9ATRPV1ALDH1A1
SCHEMBL1971938 0.77 AOC3 (1.00) AOC3GAARAB9ALMNAHTT
SCHEMBL11516529 0.76 AOC3 (0.51) AOC3RAB9A
Trifluoroacetic Acid SCHEMBL7570585 0.75 AOC3 (0.44) AOC3GAARAB9AALDH1A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020198189-A1 Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans BIOVITRUM AB (SE) 2002-12-26 US disclosed
WO-2002038153-A1 NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES BIOVITRUM AB (SE) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198189-A1 Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans AOC3, AOC2, AOC1 AOC3 1/4885GAA 558/4885RAB9A 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.